Madelyn E. Burkart
University of North Carolina at Chapel Hill
32 Papers
11 Citations
Madelyn E. Burkart is an academic researcher from University of North Carolina at Chapel Hill. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 3, co-authored 4 publications.
Chat about Author
Papers
Epitope specificity determines pathogenicity and detectability in ANCA-associated vasculitis
Aleeza J. Roth,Joshua D. Ooi,Jacob J. Hess,Mirjan M. van Timmeren,Elisabeth A. Berg,Caroline E. Poulton,Julie Anne G. McGregor,Madelyn E. Burkart,Susan L. Hogan,Yichun Hu,Witold Winnik,Patrick H. Nachman,Coen A. Stegeman,John L. Niles,Peter Heeringa,A. Richard Kitching,Stephen R. Holdsworth,J. Charles Jennette,Gloria A. Preston,Ronald J. Falk +19 more
TL;DR: Findings implicate immunodominant epitopes in the pathology of ANCA-associated vasculitis and suggest that autoantibody diversity may be common to other autoimmune diseases.
Decreased CD5⁺ B cells in active ANCA vasculitis and relapse after rituximab.
Donna O. Bunch,J. Mcgregor,Nirmal B. Khandoobhai,Nirmal B. Khandoobhai,Lydia T. Aybar,Madelyn E. Burkart,Yichun Hu,Susan L. Hogan,Caroline J. Poulton,Elisabeth A. Berg,Ronald J. Falk,Patrick H. Nachman +11 more
TL;DR: The %CD5(+) B cells, as a component of the human B regulatory cell phenotype, is a useful indicator of disease activity, remission, and future relapse, and thus may guide remission maintenance therapy after rituximab treatment.
99
Structural Racism is a Mediator of Disparities in Acute Myeloid Leukemia Outcomes.
Ivy Abraham,Garth H. Rauscher,Anand Patel,William Pearse,P Rajakumar,Madelyn E. Burkart,Ahmed Abdul Aleem,Ami Dave,Sushma Bharadwaj,Koosha Paydary,Maria Acevedo-Mendez,Krishna Goparaju,Richard Gomez,Kylie Carlson,Stephanie Tsai,John G. Quigley,John P. Galvin,Maryam Zia,Melissa C. Larson,Stephanie Berg,Wendy Stock,Jessica K. Altman,Irum Khan +22 more
TL;DR: This is the first study to formally test mediators for observed disparities in AML survival and highlights the need to investigate the mechanisms by which structural racism interacts with known prognostic and treatment factors to influence leukemia outcomes.
63
Outcomes of TP53‐mutated AML with evolving frontline therapies: Impact of allogeneic stem cell transplantation on survival
Talha Badar,Ehab Atallah,Rory M. Shallis,Aaron D Goldberg,Anand Patel,Yasmin Abaza,Jan Philipp Bewersdorf,Antoine N. Saliba,Guilherme sacchi De Camargo Correia,Guru Subramanian Guru Murthy,Adam S. DuVall,Madelyn E. Burkart,Maximilian Stahl,Yuanhang Liu,Shira Dinner,Neil Palmisiano,Mark R. Litzow,James M. Foran +17 more
TL;DR: Hematology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy Department of Oncology and Oncohematology, University of Milan, Milan.
34
Survival of TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplantation after first induction or salvage therapy: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)
Talha Badar,Ehab Atallah,Rory M. Shallis,Antoine N. Saliba,Anand Patel,Jan Philipp Bewersdorf,J. C. Grenet,Maximilian F. Stahl,Adam S. DuVall,Madelyn E. Burkart,Neil Palmisiano,Danielle Bradshaw,M. Kubiak,Shira Dinner,Aaron D Goldberg,Yasmin Abaza,Guru Subramanian Guru Murthy,Vamsi Kota,Mark R. Litzow +18 more
TL;DR: In this article , the authors conducted a multi-center study to analyze factors predicting survival among patients with TP53-mutated (m) AML receiving allogeneic hematopoietic stem cell transplant (allo-HSCT) in the recent era.